Childhood Nasopharyngeal Carcinoma: State-of-the-Art, and Questions for the Future

J Pediatr Hematol Oncol. 2018 Mar;40(2):85-92. doi: 10.1097/MPH.0000000000001054.


In children, nasopharyngeal carcinoma (NPC) is a very rare tumor, mostly Epstein-Barr Virus related and quite always diagnosed at a locally advanced stage. With current protocols associating induction cisplatin-based chemotherapy and concomitant chemoradiotherapy, prognosis is excellent with overall survival higher than 85%. However, long-term toxicities are frequent. Improvement in radiation therapy modalities like intensity-modulated radiation therapy and new strategies with radiation dose adaptation to chemotherapy response have been introduced to reduce acute and long-term toxicities. Actually, 2 main questions remain: is it possible to pursue a therapeutic deescalation in children with low-risk NPC or very good response to induction chemotherapy in order to reduce the risk of late effects? Could an immunologic maintenance treatment improve prognosis of children with high-risk NPC? International collaborative groups and prospective trials including biological studies are necessary to answer these questions to improve childhood NPC treatment and knowledge.

Publication types

  • Review

MeSH terms

  • Child
  • Humans
  • Medical Oncology / methods
  • Medical Oncology / trends
  • Nasopharyngeal Carcinoma / therapy*
  • Nasopharyngeal Neoplasms / therapy*